Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Filings indexed 1,671 across all filing types
Latest filing 2025-11-17 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Regulatory Filings Classification · 96% confidence The document is a Form 6-K filing submitted to the SEC by BioLineRx Ltd. A Form 6-K is a report used by foreign private issuers to disclose material information that is required to be made public in their home jurisdiction or provided to shareholders. The content of this specific filing is a press release announcing a patent allowance from the USPTO. Since this document does not fit into specific categories like financial reports, proxy statements, or governance reports, and is a standard regulatory disclosure of material corporate news, it is classified as a Regulatory Filing (RNS).
2025-11-17 English
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 5,000 characters) from BioLineRx submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on BioLineRx Announces Receipt of USPTO Notice of Allowance...' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the report itself, making it a Report Publication Announcement (RPA).
2025-11-17 English
6-K
Foreign Filer Report
2025-09-29 English
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by BioLineRx Ltd. It details a joint venture transaction, including the full text of an Asset Transfer Agreement and references to a Collaboration and Shareholders Agreement. While it contains M&A-related content, Form 6-K filings by foreign private issuers are standard regulatory disclosures. Since the document provides the full legal agreements and details of the transaction rather than just an announcement of a report, it falls under the 'Regulatory Filings' category as the most appropriate classification for this type of SEC filing.
2025-09-29 English
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 2,100 characters) from BioLineRx Ltd. submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' and provides a filename 'FORM_6-K_29-Sep-25_isa.pdf'. According to the 'Menu vs Meal' rule, a document that announces the publication or attachment of another report is classified as a Report Publication Announcement (RPA).
2025-09-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.